276 related articles for article (PubMed ID: 9690722)
21. Rebound hypersecretion after H2-antagonist withdrawal--a comparative study with nizatidine, ranitidine and famotidine.
Fullarton GM; Macdonald AM; McColl KE
Aliment Pharmacol Ther; 1991 Aug; 5(4):391-8. PubMed ID: 1685675
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the effects of placebo, ranitidine, famotidine and nizatidine on intragastric acidity by means of continuous pH recording.
Savarino V; Mela GS; Zentilin P; Scalabrini P; Bonifacino G; Gambaro P; Celle G
Digestion; 1989; 42(1):1-6. PubMed ID: 2568299
[TBL] [Abstract][Full Text] [Related]
23. A controlled comparison of continuous ranitidine and intermittent famotidine infusions on gastric pH.
Bachmann K; Sullivan TJ; Jauregui L
J Clin Pharmacol; 1993 Dec; 33(12):1219-24. PubMed ID: 7907348
[TBL] [Abstract][Full Text] [Related]
24. Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast-dissolving tablets to fasting healthy volunteers.
Hedenström H; Alm C; Kraft M; Grahnén A
Aliment Pharmacol Ther; 1997 Dec; 11(6):1137-41. PubMed ID: 9663842
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of intragastric acidity in healthy subjects dosed with ranitidine 75 mg: a comparative study with cimetidine and placebo.
Grimley CE; Constantinides S; Snell CC; Mills JG; Nwokolo CU
Aliment Pharmacol Ther; 1997 Oct; 11(5):875-9. PubMed ID: 9354195
[TBL] [Abstract][Full Text] [Related]
26. Comparison of gastric mucosal surface pH response times after intravenous administration of histamine2-receptor antagonists.
Katsu K; Yabe S
Clin Ther; 1995; 17(3):433-10. PubMed ID: 7585847
[TBL] [Abstract][Full Text] [Related]
27. Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade.
Nwokolo CU; Smith JT; Sawyerr AM; Pounder RE
Gut; 1991 Dec; 32(12):1455-60. PubMed ID: 1685465
[TBL] [Abstract][Full Text] [Related]
28. The effects of roxatidine acetate (HOE-760) on 24-hour intragastric acidity in healthy volunteers: comparison with ranitidine and placebo.
Merki HS; Witzel L; Kaufmann D; Kempf M; Müssig V; Neumann J; Scheurle E; Röhmel J; Walt RP
Aliment Pharmacol Ther; 1988 Feb; 2(1):73-81. PubMed ID: 2908751
[TBL] [Abstract][Full Text] [Related]
29. Effects of a single low dose of ranitidine and effervescent antacids on intragastric acidity in healthy volunteers.
Améndola R; Santos MC; Massa JM; Vazquez H; Smecuol E
Acta Gastroenterol Latinoam; 2007 Dec; 37(4):231-7. PubMed ID: 18254261
[TBL] [Abstract][Full Text] [Related]
30. Ranitidine suspension or famotidine resoriblette and gastric fluid volume and pH.
Oikkonen M; Erkola O; Collan R
Can J Anaesth; 1995 Sep; 42(9):793-6. PubMed ID: 7497560
[TBL] [Abstract][Full Text] [Related]
31. Statistical interpretation of the antisecretory effect of famotidine measured by intragastric pH-metry.
Hunyady B; Juricskay I; Nagy L; Garamszegi M; Vincze A; Mózsik G
Eur J Clin Pharmacol; 1996; 50(6):449-56. PubMed ID: 8858270
[TBL] [Abstract][Full Text] [Related]
32. [Inhibition of 24-hour acidity by nizatidine].
Dammann HG; Dreyer M; Gottlieb WR; Wolf N; Müller P; Simon B
Fortschr Med; 1989 May; 107(14):321-4. PubMed ID: 2568971
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children.
Madani S; Kauffman R; Simpson P; Lehr VT; Lai ML; Sarniak A; Tolia V
J Clin Pharmacol; 2014 Feb; 54(2):201-5. PubMed ID: 24258773
[TBL] [Abstract][Full Text] [Related]
34. Low-dose famotidine and effervescent cimetidine in healthy subjects: a placebo-controlled overnight pH study.
Reilly TG; Grimley CE; Usselmann B; Cottrell J; Mann SG; Raskin S; Nwokolo CU
Aliment Pharmacol Ther; 1998 May; 12(5):469-74. PubMed ID: 9663728
[TBL] [Abstract][Full Text] [Related]
35. Tolerance to oral H2-receptor antagonists.
Wilder-Smith CH; Ernst T; Gennoni M; Zeyen B; Halter F; Merki HS
Dig Dis Sci; 1990 Aug; 35(8):976-83. PubMed ID: 1974493
[TBL] [Abstract][Full Text] [Related]
36. Impact of chronic oral H2-antagonist therapy on left ventricular systolic function and exercise capacity.
Hilleman DE; Mohiuddin SM; Williams MA; Gannon JM; Mathias RJ; Thalken LJ
J Clin Pharmacol; 1992 Nov; 32(11):1033-7. PubMed ID: 1361935
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and pharmacodynamics of ranitidine and famotidine in healthy elderly subjects: a double-blind, placebo-controlled comparison.
Bisson C; St-Laurent M; Michaud JT; LeBel M
Pharmacotherapy; 1993; 13(1):3-9. PubMed ID: 8437966
[TBL] [Abstract][Full Text] [Related]
38. Smoking and pH response to H2-receptor antagonists.
Schürer-Maly CC; Varga L; Koelz HR; Halter F
Scand J Gastroenterol; 1989 Dec; 24(10):1172-8. PubMed ID: 2690314
[TBL] [Abstract][Full Text] [Related]
39. The action of 10 mg famotidine versus 200 mg cimetidine: onset and magnitude of antisecretory action within the first 2 hours after administration.
Decktor D; Houle JM; Pierce CH
Am J Ther; 1998 Mar; 5(2):97-100. PubMed ID: 10099044
[TBL] [Abstract][Full Text] [Related]
40. Over-the-counter H(2)-receptor antagonists do not compromise intragastric pH control with proton pump inhibitors.
Tutuian R; Katz PO; Ahmed F; Korn S; Castell DO
Aliment Pharmacol Ther; 2002 Mar; 16(3):473-7. PubMed ID: 11876700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
